Biogen Inc. ( NASDAQ: BIIB) Stifel 2025 Virtual CNS Forum Conference March 18, 2025 10:15 AM ET Great. Good morning, everybody. Happy to be moderating my annual panel where Priya has to listen to me ...
Shares of Stoke Therapeutics sank Tuesday as the drugmaker said its CEO Dr. Edward Kaye is stepping down from his role.
Health Canada has granted approval for Biogen’s Skyclarys (omaveloxolone) to treat Friedreich’s ataxia (FA), a rare, ...
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing ...
Raziel Green, 52, an active runner and mother of two, was diagnosed with a rare form of ALS in 2017. Since starting a ...
Bullish option flow detected in Biogen (BIIB) with 2,556 calls trading, 1.5x expected, and implied vol increasing over 1 point to 34.69%.
As the only approved treatment to address disease progression, SKYCLARYS addresses a long-standing gap in the care of Canadians living with Friedreich's ataxia Friedreich's ...
Biogen Canada Inc. is pleased to announce that Health Canada has approved SKYCLARYStm (omaveloxolone) for the treatment of Friedreich's ataxia (FA) in patients 16 years of age and older.2 This ...
Neurotech Reports, the publisher of the Neurotech Business Report and BioElectRx Business Report newsletters, announced that ...
Biogen Canada Inc. is pleased to announce that Health Canada has approved SKYCLARYS™ (omaveloxolone) for the treatment of Friedreich's ataxia (FA) in patients 16 years of age and older.2 This approval ...
Read the Market Summary Here:- https://reportocean.com/industry-verticals/sample-request?report_id=bw8526 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback